Cynata Therapeutics wraps up patient enrollment for diabetic foot ulcers clinical trial
In a significant development for diabetic foot ulcer treatments, Cynata Therapeutics Limited (ASX: CYP), a leading clinical-stage biotechnology company, has announced the completion of patient enrollment in its Phase 1 clinical trial. This trial evaluates the efficacy of CYP-006TK, a novel cell therapeutic developed by Cynata, for treating diabetic foot ulcers (DFU), a common yet […]